FCM
KALA icon

Flinton Capital Management’s KALA BIO KALA Stock Holding History

Flinton Capital Management’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3
Closed -$91K – 867
2018
Q2 		$91K Hold
3
– – ﹤0.01% 776
2018
Q1 		$99K Buy
+3
New +$114K ﹤0.01% 757

Other funds holding KALA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Flinton Capital Management's KALA Position: Q3 2018 in Review

Flinton Capital Management sold out of KALA BIO (KALA) in Q3 2018, closing a stake of 3 shares — an estimated $91K sold.

Flinton Capital Management first reported a position in KALA in Q1 2018 and held it in 2 quarters. The position peaked at $99K in Q1 2018. 59 funds tracked by Wall St. Rank hold KALA as of Q3 2018.

  • Flinton Capital Management reported no remaining KALA BIO position as of Q3 2018 after selling out during the quarter.
  • Flinton Capital Management sold 3 KALA BIO shares in Q3 2018, an estimated $91K.
  • Flinton Capital Management first reported a position in KALA BIO in Q1 2018 and held it in 2 quarters.
  • Flinton Capital Management's KALA BIO position peaked at $99K in Q1 2018.
  • 59 funds tracked by Wall St. Rank held KALA BIO as of Q3 2018.

Based on Flinton Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.